Heparin or bivalirudin for non-primary PCI: Beware of neat and simple answers….
Efthymios N DeliargyrisCarey D KimmelstielPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
The debate regarding the choice of heparin or bivalirudin as the preferred anticoagulant in PCI is still ongoing Nonrandomized registry data are severely limited for comparative analyses and should therefore always be interpreted with caution Clinicians should resist simplistic data interpretations or populist cries relating to cost, but rather focus on valid benefit:risk analyses for their clinical decision making.
Keyphrases
- percutaneous coronary intervention
- venous thromboembolism
- decision making
- st segment elevation myocardial infarction
- coronary artery disease
- acute myocardial infarction
- acute coronary syndrome
- atrial fibrillation
- st elevation myocardial infarction
- antiplatelet therapy
- electronic health record
- coronary artery bypass grafting
- big data
- growth factor
- palliative care
- coronary artery bypass
- machine learning
- heart failure